Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock

Clin Toxicol (Phila). 2016 Nov;54(9):881-885. doi: 10.1080/15563650.2016.1209768. Epub 2016 Jul 21.

Abstract

Objective: Acute beta-blocker overdose can cause severe cardiac dysfunction. Chronic toxicity is rare but potentially severe. We report therapeutic dosing of metoprolol resulting in unusual pharmacokinetics and toxicity, given high-dose insulin therapy for treatment.

Case details: A 90-year-old female presented with hypotension, tachycardia and severe cardiac dysfunction after commencing a rapidly increasing metoprolol dose of 250 mg split daily. She was admitted to intensive care and given high-dose insulin therapy (10 U/kg/h), noradrenaline, adrenaline and dobutamine for severe cardiac dysfunction (cardiac index, 0.76 L/min/m2). She developed acute renal failure, ischaemic hepatitis and disseminated intravascular coagulopathy. Inotropes and high-dose insulin were weaned over four days with complete recovery. Metoprolol was quantified with liquid chromatography-tandem mass spectrometry and concentration-time data were analysed using MONOLIX® vs 4.3 ( www.lixoft.com ). Admission metoprolol concentration was 2.39 μg/mL (therapeutic reference range: 0.035-0.5 μg/mL). Data best fitted a one compartmental model with Michaelis-Menten kinetics and zero order elimination at high concentrations. Final parameter estimates were V, 63.4 L, maximum rate [Vm], 9.57 mg h-1, Michaelis constant [Km], 1.97 mg L-1. Predicted elimination half-life decreased from 20 h over time until there was first order elimination with a half-life 9 h.

Conclusion: The time course of cardiac dysfunction was longer than acute overdose but consistent with prolonged zero order elimination of metoprolol, suggesting the patient was a poor CYP2D6 metaboliser. High-dose insulin euglycaemia appeared to be effective in combination with vasoconstrictors/inotropes.

Keywords: Beta-blocker; Michaelis–Menten; high-dose insulin therapy; pharmacokinetics; toxicity.

Publication types

  • Case Reports

MeSH terms

  • Adrenergic beta-2 Receptor Antagonists / administration & dosage
  • Adrenergic beta-2 Receptor Antagonists / adverse effects*
  • Adrenergic beta-2 Receptor Antagonists / pharmacokinetics
  • Aged, 80 and over
  • Chromatography, Liquid / methods
  • Cytochrome P-450 CYP2D6 / metabolism
  • Dose-Response Relationship, Drug
  • Female
  • Half-Life
  • Humans
  • Hypotension / chemically induced*
  • Insulin / administration & dosage
  • Metoprolol / administration & dosage
  • Metoprolol / adverse effects*
  • Metoprolol / pharmacokinetics
  • Shock, Cardiogenic / chemically induced*
  • Tandem Mass Spectrometry / methods
  • Vasoconstrictor Agents / administration & dosage

Substances

  • Adrenergic beta-2 Receptor Antagonists
  • Insulin
  • Vasoconstrictor Agents
  • Cytochrome P-450 CYP2D6
  • Metoprolol